These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 20236863)

  • 1. Rifamycins--obstacles and opportunities.
    Aristoff PA; Garcia GA; Kirchhoff PD; Showalter HD
    Tuberculosis (Edinb); 2010 Mar; 90(2):94-118. PubMed ID: 20236863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis pharmacotherapy: strategies to optimize patient care.
    Mitnick CD; McGee B; Peloquin CA
    Expert Opin Pharmacother; 2009 Feb; 10(3):381-401. PubMed ID: 19191677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.
    Regazzi M; Carvalho AC; Villani P; Matteelli A
    Clin Pharmacokinet; 2014 Jun; 53(6):489-507. PubMed ID: 24777631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment options for multidrug-resistant tuberculosis.
    Field SK; Fisher D; Jarand JM; Cowie RL
    Ther Adv Respir Dis; 2012 Oct; 6(5):255-68. PubMed ID: 22763676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of rifamycins in HIV-infected patients.
    Preboth M
    Am Fam Physician; 2000 Sep; 62(5):1189-90. PubMed ID: 10997538
    [No Abstract]   [Full Text] [Related]  

  • 8. Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages.
    Dhillon J; Mitchison DA
    Am Rev Respir Dis; 1992 Jan; 145(1):212-4. PubMed ID: 1309967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Review article titled, "Rifamycins - Obstacles and opportunities" by Paul A. Aristoff, George A. Garcia, Paul D. Kirchhoff, H.D. Hollis Showalter. Tuberculosis 2010; 90(2):94-118.
    Sayada C
    Tuberculosis (Edinb); 2010 Sep; 90(5):326; author reply 326-7. PubMed ID: 20691638
    [No Abstract]   [Full Text] [Related]  

  • 10. In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria.
    Dickinson JM; Mitchison DA
    Tubercle; 1987 Sep; 68(3):177-82. PubMed ID: 2834842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current status and perspectives on the development of rifamycin derivative antibiotics].
    Hidaka T
    Kekkaku; 1999 Jan; 74(1):53-61. PubMed ID: 10067056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug resistant tuberculosis].
    Zwolska Z; Augustynowicz-Kopeć E
    Pol Merkur Lekarski; 2011 May; 30(179):362-6. PubMed ID: 21675144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.
    Gill SK; Garcia GA
    Tuberculosis (Edinb); 2011 Sep; 91(5):361-9. PubMed ID: 21704562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Frequency of drug resistant tuberculosis in Poland in 2000 as compared to 1997].
    Augustynowicz-Kopeć E; Zwolska Z; Jaworski A; Kostrzewa E; Klatt M; Swiderska A; Drozd I
    Pneumonol Alergol Pol; 2002; 70(3-4):193-202. PubMed ID: 12271966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis.
    Heifets LB; Lindholm-Levy PJ; Iseman MD
    Am Rev Respir Dis; 1988 Mar; 137(3):719-21. PubMed ID: 2830815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB; Karaoui LR; Mansour H
    Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV infection and multidrug-resistant tuberculosis: the perfect storm.
    Wells CD; Cegielski JP; Nelson LJ; Laserson KF; Holtz TH; Finlay A; Castro KG; Weyer K
    J Infect Dis; 2007 Aug; 196 Suppl 1():S86-107. PubMed ID: 17624830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
    Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA
    Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The early bactericidal activity of rifabutin measured by sputum viable counts in Hong Kong patients with pulmonary tuberculosis.
    Chan SL; Yew WW; Ma WK; Girling DJ; Aber VR; Felmingham D; Allen BW; Mitchison DA
    Tuber Lung Dis; 1992 Feb; 73(1):33-8. PubMed ID: 1326348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The early bactericidal activities of rifampin and rifapentine in pulmonary tuberculosis.
    Sirgel FA; Fourie PB; Donald PR; Padayatchi N; Rustomjee R; Levin J; Roscigno G; Norman J; McIlleron H; Mitchison DA
    Am J Respir Crit Care Med; 2005 Jul; 172(1):128-35. PubMed ID: 15805182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.